TRImaran was formed around the patent portfolio developed by Dr. Aloke Dutta, Professor of Pharmaceutics at the School of Pharmacy, Wayne State University in Detroit. The three lead compounds from the portfolio are structurally novel, pharmacologically distinct, and functionally best characterized as triple reuptake inhibitors (TRI). Their activity suggests potential clinical utility in a number of conditions including Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), Attention Deficit-Hyperactivity Disorder (ADHD) and other conditions including pain and

addictive disorders, depending on their pharmacology. All three compounds are covered by patents already issued with coverage, including regulatory extension, through 2033.

TRImaran is a ‘virtual’ company. All development activities are outsourced.